+57.7%
CVE vs GSK
+63.2%
-5.6%
-49.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.6% | -0.2% | -0.4% | -0.6% |
| 7D | -16.1% | +1.7% | -17.8% | -16.0% |
| 30D | -10.4% | +7.0% | -17.4% | -10.2% |
| 3M | -2.4% | -2.7% | +0.3% | -2.3% |
| 6M | -4.4% | +1.4% | -5.9% | -4.4% |
| YTD | +64.9% | +5.3% | +59.6% | +63.9% |
| 1Y | +66.0% | +10.6% | +55.4% | +64.7% |
| 3Y | +57.7% | +62.6% | -4.9% | +36.9% |
| All | +57.7% | +63.2% | -5.6% | +36.9% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling